First Tracks Biotherapeutics (TRAX) Stock Price & Analysis
Score
AI Analysis
SnapshotFirst Tracks Biotherapeutics is a growth-led story right now — Growth 98/100 is the pillar doing the heavy lifting (overall 61/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~57% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
First Tracks Biotherapeutics Inc (TRAX) last printed $45.38. Equity value is $1.98B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2023 | 2024 | 2025 |
|---|---|---|
| $0.00 | $0.00 | $0.00 |
About
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.